- Home
- CCCC vs OPP Comparison
CCCC vs OPP Comparison
Compare CCCC & OPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CCCC | OPP |
|---|---|---|
| Founded | 2015 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.3M | 204.0M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | CCCC | OPP |
|---|---|---|
| Price | $2.42 | $7.82 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 108.0K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 14.41% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,108,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.09 | $7.26 |
| 52 Week High | $4.70 | $8.83 |
Technical Indicators
Market Signals| Indicator | CCCC | OPP |
|---|---|---|
| Relative Strength Index (RSI) | 46.82 | 31.20 |
| Support Level | $2.50 | $7.94 |
| Resistance Level | $2.69 | $8.03 |
| Average True Range (ATR) | 0.18 | 0.07 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 10.21 | 5.30 |
Price Performance
Historical ComparisonAbout CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
About OPP RiverNorth/DoubleLine Strategic Opportunity Fund Inc.
RiverNorth/DoubleLine Strategic Opportunity Fund Inc is a closed-end management investment company. The company's investment objective is to seek current income and overall total return.